Threshold Pharmaceuticals Announces Results of Annual Meeting of Stockholders
August 01, 2017 09:15 ET
|
Threshold Pharmaceuticals, Inc.
MENLO PARK, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) announced today that its stockholders approved all of the proposals presented at the Annual...
Threshold Pharmaceuticals Reports Second Quarter Financial Results
July 31, 2017 17:45 ET
|
Threshold Pharmaceuticals, Inc.
MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the second quarter ended June 30, 2017 and provided an update...
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab
June 13, 2017 08:01 ET
|
Threshold Pharmaceuticals, Inc.
-- Phase 1 clinical trial will evaluate the effect of ipilimumab and evofosfamide (TH-302) in advanced solid tumors -- -- Company management to host “Hypoxia and Immunotherapy” conference call today...
Threshold Pharmaceuticals Reports First Quarter Financial Results
May 15, 2017 16:24 ET
|
Threshold Pharmaceuticals, Inc.
- Definitive merger agreement between Threshold and Molecular Templates expected to close mid-2017 - - Initiation of the Phase 1 clinical trial of evofosfamide in combination with ipilumumab at the...
Threshold Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
March 27, 2017 16:01 ET
|
Threshold Pharmaceuticals, Inc.
-- Recently proposed merger with Molecular Templates will result in Nasdaq-listed company focused on developing novel treatments for cancer -- SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE...
Threshold Pharmaceuticals and Molecular Templates Agree to Combine
March 17, 2017 06:55 ET
|
Threshold Pharmaceuticals, Inc.
-- Transaction to result in Nasdaq-listed company focused on developing novel treatments for cancer -- -- Molecular Templates lead drug candidate being developed to treat non-Hodgkin’s Lymphoma...
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424
December 19, 2016 08:02 ET
|
Threshold Pharmaceuticals, Inc.
-- Preclinical studies will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia cancer cell lines with high AKR1C3 expression -- SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 ...
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel Healthcare Conference 2016
November 15, 2016 16:05 ET
|
Threshold Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today...
Threshold Pharmaceuticals Reports Third Quarter Financial Results
November 07, 2016 08:00 ET
|
Threshold Pharmaceuticals, Inc.
-- Planning to initiate a clinical trial of evofosfamide in combination with checkpoint inhibitors -- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc....
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
September 29, 2016 18:03 ET
|
Threshold Pharmaceuticals, Inc.
-- Tarloxotinib Primary Interim Response Rate Endpoint Achieved in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (SCCS) but not Achieved in Patients with Metastatic...